GeneCentric Acquires Select ImmunoGenomics

Acquisition Effective August 15, 2019

Read full press release
  • This combination of GeneCentric and Select ImmunoGenomics resources and capabilities provides unparalleled genomics solutions to drive precision oncology and accelerate successful drug development
  • Unique platform enables rapid molecular profiler development, identifying patient-responders for oncology drugs, improving response rates and durability, and ultimately patient outcomes
  • Drs. Vincent and Parker joining GeneCentric Therapeutics as ongoing Scientific Advisors
For further information, contact:
Philippe Chemla, Chief Business Officer
GeneCentric Therapeutics, Inc.
Select ImmunoGenomics
Precision Bioinformatics

Established in 2015 to provide unique, deep expertise in immunogenomics analysis and interpretation, Select ImmunoGenomics offers full stack experimental design, data analysis, advanced algorithm applications, biomarker development services and publication support through a platform that combines laboratory and informatics research.

Clients include Pharmaceutical, Biotech and Diagnostics companies.

Select ImmunoGenomics
Joel Parker, PhD
Genomics & Data Science
Benjamin Vincent, MD, PhD
Computational Immunology